Acotiamide hydrochloride is under clinical development by Zeria Pharmaceutical and currently in Phase III for Functional (Non Ulcer) Dyspepsia. According to GlobalData, Phase III drugs for Functional (Non Ulcer) Dyspepsia does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Acotiamide hydrochloride LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Acotiamide hydrochloride overview
Acotiamide hydrochloride (Acofide, YM-443, and Z-338) is a member of a class of prokinetic agents and it is an upper gastrointestinal motility modulator. It is formulated as film-coated tablets for oral route of administration. Acofide is indicated for the treatment of postprandial fullness, upper abdominal bloating, and early satiation due to functional dyspepsia.
It is under development for the treatment of functional dyspepsia and esophageal gastric junction outflow obstruction. The drug candidate acts by targeting acetylcholinesterases. It was also under development for functional dyspepsia in the US and North America.
Zeria Pharmaceutical overview
Zeria Pharmaceutical (Zeria) manufactures and distributes pharmaceutical and consumer healthcare products. The company’s pharmaceutical products include drugs for the treatment of ulcerative colitis, Crohn’s disease, functional dyspepsia, gastritis and ulcers and other gastrointestinal diseases. It offers combination granules, calcium channel blockers, anti-leukopenia and iron deficiency anemia agents. Zeria also markets OTC drugs for arthralgia and lumbalgia, physical fatigue and exhaustion and soft drinks, among others. Zeria is headquartered in Chuo-Ku, Tokyo, Japan.
For a complete picture of Acotiamide hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
